What this is
- How it works
- How it works isn't classified yet
- Tested for
- Optic Neuritis
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).”In the company’s words, NCT07623668 on ClinicalTrials.gov
- Other names
- OCS-05
Other drugs for Optic Neuritis
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- SatralizumabRoche · Phase 3
- B001Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
- DivozilimabBiocad · Phase 3
- MIL62Beijing Mabworks Biotech Co., Ltd. · Phase 3
Coming up1
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research | |
| Phase 2Completed | 16 Sep 2024 | OCS-05 in Patients With Optic Neuritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026